Bevacizumab price in Bangladesh (2026)
Bangladesh list prices converted into BDT, plus the registration rules of the DGDA, the legal import routes and the real cost build-up for Bangladesh.
Currency conversion
| Item | BDT | BDT | USD |
|---|
Bangladesh benchmark (world reference price)
Registered brands and list prices for this molecule in Bangladesh (DGDA registration, via MedEx).
| Brand | Manufacturer | Strength | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Abevmy | Beximco Pharmaceuticals Ltd. | 100 mg/4 ml IV Infusion | — | — | — |
| Abevmy | Beximco Pharmaceuticals Ltd. | 400 mg/16 ml IV Infusion | — | — | — |
| Bevacimab | Healthcare Pharmaceuticals Ltd. | 400 mg/16 ml IV Infusion | — | — | — |
| Bevacimab | Healthcare Pharmaceuticals Ltd. | 100 mg/4 ml IV Infusion | — | — | — |
| Bevaris | Aristopharma Ltd. | 100 mg/4 ml IV Infusion | — | — | — |
| Bevaris | Aristopharma Ltd. | 400 mg/16 ml IV Infusion | — | — | — |
| Bevastim | Beacon Pharmaceuticals PLC | 100 mg/4 ml IV Infusion | — | — | — |
| Bevastim | Beacon Pharmaceuticals PLC | 400 mg/16 ml IV Infusion | — | — | — |
| Bevixa | Incepta Pharmaceuticals Ltd. | 100 mg/4 ml IV Infusion | — | — | — |
| Bevixa | Incepta Pharmaceuticals Ltd. | 400 mg/16 ml IV Infusion | — | — | — |
| Vegzelma | ZAS Corporation (Mfg. by: Celltrion Pharma Inc, Korea) | 100 mg/4 ml IV Infusion | — | — | — |
| Vegzelma | ZAS Corporation (Mfg. by: Celltrion Pharma Inc, Korea) | 400 mg/16 ml IV Infusion | — | — | — |
| Avastin Originator | Roche Bangladesh Ltd. | 100 mg/4 ml IV Infusion | — | — | — |
| Avastin Originator | Roche Bangladesh Ltd. | 400 mg/16 ml IV Infusion | — | — | — |
Source: MedEx Bangladesh drug registry (list prices of DGDA-registered brands). Unit prices move with pack size, pharmacy and exchange rate — reference only. Original registry page
Import and regulatory notes
Directorate General of Drug Administration (DGDA). Bangladesh is the reference market for this price guide: it is a least-developed-country WTO member with a patent exemption for pharmaceuticals until 2033, so local manufacturers legally produce on-patent molecules. Products are registered with the DGDA and carry a Bangladesh MRP; buying at pharmacy level usually means a per-strip or per-box price in BDT.
How to obtain it legally
- Obtain a prescription plus the diagnostic/genetic report from the treating physician (e.g. the target-mutation result).
- Confirm the exact brand and strength, and ask the supplier for the batch number, certificate of analysis (COA) and the manufacturer's GMP credentials.
- Clear the shipment through a DGDA-licensed importer or pharmacy; unregistered products go through the named-patient route.
- Check batch number, expiry and packaging on arrival, then follow the prescriber's monitoring schedule.
What adds to the price when you import
- International freight and cold chain (monoclonal antibodies and insulins need 2–8°C end-to-end).
- Customs duty and import VAT in Bangladesh.
- Compliance, licensing and warehousing cost of the importer/distributor (typically 10–30%).
- Order size and pack configuration — full cases price below retail strips.
- Exchange-rate movement: this page converts at 1 USD = 122.87 BDT.
Availability in Southeast Asia
| Country | Status | Notes |
|---|---|---|
| Bangladesh | Multiple local biosimilars marketed | Five or more locally produced bevacizumab biosimilars (Beacon Bevastim, Beximco Abevmy, Healthcare Bevacimab, Aristopharma Bevaris, Incepta Bevixa) plus Celltrion Vegzelma are listed in MedEx alongside Roche's originator Avastin. |
Frequently asked questions
How much does bevacizumab cost in Bangladesh?
No published price data recorded for this molecule.
Can I legally import bevacizumab into Bangladesh?
Yes, but only through the rules of the Directorate General of Drug Administration (DGDA): Bangladesh is the reference market for this price guide: it is a least-developed-country WTO member with a patent exemption for pharmaceuticals until 2033, so local manufacturers legally produce on-patent molecules. Products are registered with the DGDA and carry a Bangladesh MRP; buying at pharmacy level usually means a per-strip or per-box price in BDT. Prescription medicines must move on a valid prescription through a licensed importer, pharmacy or hospital; personal-use imports need a named-patient / compassionate-use authorisation.
Are Bangladeshi or Indian generics of bevacizumab approved in Bangladesh?
We cannot confirm the registration status of every individual generic brand in Bangladesh. Directorate General of Drug Administration (DGDA) is the approving authority, and only products with a local product registration (or a special import authorisation) may be sold routinely. Ask your supplier for the local registration or import permit for the specific brand before you buy.
Why is the Bangladesh price a useful reference?
Bangladesh is a least-developed-country WTO member with a pharmaceutical patent exemption running to 2033, so local manufacturers can legally produce molecules that are still on patent elsewhere — and DGDA-registered list prices are public. That makes it the practical global floor price for on-patent targeted therapy and the benchmark used in import negotiations.
What is the availability situation for bevacizumab in Bangladesh?
Bangladesh: Multiple local biosimilars marketed. Five or more locally produced bevacizumab biosimilars (Beacon Bevastim, Beximco Abevmy, Healthcare Bevacimab, Aristopharma Bevaris, Incepta Bevixa) plus Celltrion Vegzelma are listed in MedEx alongside Roche's originator Avastin.
This molecule in other markets
This page is an information resource for healthcare professionals, licensed importers and patients under medical care. It is not medical advice, not a prescription service, and not an offer to sell prescription medicines to the public.
Also sourced for Bangladesh
Need a verified quotation?
Send us the molecule, strength, pack size, quantity and destination country. We reply with a batch-traceable quotation, certificates of analysis and shipping documentation.
We supply licensed pharmacies, hospitals, importers and distributors — not direct-to-consumer patients.